Top

Published in:

Open Access 01-12-2014 | Case report

The more you look, the more you find: challenging results on FDG-PET CT in a patient with neurofibromatosis type I

Authors: Patrick Schöffski, Christophe M Deroose, Olivier Gheysens, Nele Lips, Koen Slabbaert, Ben Vancleynenbreugel, Philippe Moerman, Willy E Peetermans

Published in: BMC Medical Imaging | Issue 1/2014

Abstract

Background

FDG-PET/CT is part of the standard diagnostic management of a patients with a large variety of common and less common malignant tumors, based on the increased glucose metabolism within tumors.

Case presentation

A hybrid fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) was performed in a neurofibromatosis patient to rule out relapse of malignant peripheral nerve sheet tumor. The scan revealed non-malignant neurofibromas, a testis seminoma and hypermetabolic syphilitic granulomata.

Conclusion

This case stresses the need to rule out infectious diseases when atypical hypermetabolic lesions are present.

Available only for authorised users

Ferner RE, Golding JF, Smith M, Calonje E, Jan W, Sanjayanathan V, O'Doherty M: [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study. Ann Oncol. 2008, 19 (2): 390-394. 10.1093/annonc/mdm450.CrossRefPubMed

Cremerius U, Effert PJ, Adam G, Sabri O, Zimmy M, Wagenknecht G, Jakse G, Buell U: FDG PET for detection and therapy control of metastatic germ cell tumor. J Nucl Med. 1998, 39 (5): 815-822.PubMed

Krege S, Beyer J, Souchon R, Albers P, Albrecht W, Algaba F, Bamberg M, Bodrogi I, Bokemeyer C, Cavallin-Stahl E, Classen J, Clemm C, Cohn-Cedermark G, Culine S, Daugaard G, De Mulder PH, De Santis M, de Wit M, de Wit R, Derigs HG, Dieckmann KP, Dieing A, Droz JP, Fenner M, Fizazi K, Flechon A, Fossa SD, del Muro XG, Gauler T, Geczi L, et al: European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Eur Urol. 2008, 53: 478-496. 10.1016/j.eururo.2007.12.024.CrossRefPubMed

De Santis M, Becherer A, Bokemeyer C, Stoiber F, Oechsle K, Sellner F, Lang A, Kletter K, Dohmen BM, Dittrich C, Pont J: 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004, 22: 1034-1039. 10.1200/JCO.2004.07.188.CrossRef

Kosters K, Bleeker-Rovers CP, van Crevel R, Oyen WJ, van der Ven AJ: Aortitis diagnosed by F-18-fluorodeoxyglucose positron emission tomography in a patient with syphilis and HIV coinfection. Infection. 2005, 33 (5–6): 387-389.CrossRefPubMed

Dijkman BG, Schuurbiers OC, Vriens D, Looijen-Salamon M, Bussink J, Timmer-Bonte JN, Snoeren MM, Oyen WJ, van der Heijden HF, de Geus-Oei LF: The role of (18)F-FDG PET in the differentiation between lung metastases and synchronous second primary lung tumours. Eur J Nucl Med Mol Imaging. 2010, 37 (11): 2037-2047. 10.1007/s00259-010-1505-2.CrossRefPubMedPubMedCentral

Hartley N, Rajesh A, Verma R, Sinha R, Sandrasegaran K: Abdominal manifestations of neurofibromatosis. J Comput Assist Tomogr. 2008, 32 (1): 4-8. 10.1097/rct.0b013e318054e1ca.CrossRefPubMed

Groot-Loonen JJ, Voute PA, de Kraker J: Testicular tumor concomitant with von Recklinghausen's disease. Med Pediatr Oncol. 1988, 16 (2): 116-117. 10.1002/mpo.2950160210.CrossRefPubMed

Pasmant E, Vidaud M, Vidaud D, Wolkenstein P: Neurofibromatosis type 1: from genotype to phenotype. J Med Genet. 2012, 49 (8): 483-489. 10.1136/jmedgenet-2012-100978.CrossRefPubMed

The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2342/14/19/prepub

Title: The more you look, the more you find: challenging results on FDG-PET CT in a patient with neurofibromatosis type I
Authors: Patrick Schöffski
Christophe M Deroose
Olivier Gheysens
Nele Lips
Koen Slabbaert
Ben Vancleynenbreugel
Philippe Moerman
Willy E Peetermans
Publication date: 01-12-2014
Publisher: BioMed Central
Published in: BMC Medical Imaging / Issue 1/2014
Electronic ISSN: 1471-2342
DOI: https://doi.org/10.1186/1471-2342-14-19

At a glance: The STEP trials

Springer Medicine

The more you look, the more you find: challenging results on FDG-PET CT in a patient with neurofibromatosis type I

Abstract

Background

Case presentation

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Case presentation

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2014

Intelligent neonatal monitoring based on a virtual thermal sensor

Mammographic images segmentation based on chaotic map clustering algorithm

Myofibre segmentation in H&E stained adult skeletal muscle images using coherence-enhancing diffusion filtering

Diffusion-weighted MRI characteristics of the cerebral metastasis to brain boundary predicts patient outcomes

Specific CT 3D rendering of the treatment zone after Irreversible Electroporation (IRE) in a pig liver model: the “Chebyshev Center Concept” to define the maximum treatable tumor size

A case of multiple hepatic angiomyolipomas with high 18 F-fluorodeoxyglucose uptake